chemotherapy/vomiting

BACKGROUND OF THE INVENTION 1. Field of Invention Cisplatin (cis-dichlorodiammine platinum II) is one of the more effective drugs used in cancer chemotherapy; however, the resulting violent emesis interferes with acceptance of therapy by the patient. This invention relates to an improvement in the

This application is a U.S. national stage of PCT/EP2010/000,204 filed on Jan. 15, 2010 which claims priority to and the benefit of Italian Application No. MI200,9000,049 filed on Jan. 20, 2009, the contents of which are incorporated herein by reference. SUMMARY OF THE INVENTION The present invention

SUMMARY OF THE INVENTION The present invention relates to compositions consisting of an association of lipophilic extracts of Zingiber officinale and Echinacea angustifolia, which are useful for the prevention and treatment of oesophageal reflux and chemotherapy-induced emesis. PRIOR ART Cancer of

This application is a .sctn.371 national stage of PCT International Application No. PCT/EP2011/058224, filed May 20, 2011, claiming priority of European Patent Application EP 10382136.9, filed May 21, 2010, the contents of all of which are hereby incorporated by reference into this

FIELD OF THE INVENTION The present invention relates to the use of centrally acting NK.sub.1 antagonists to treat nausea and vomiting, particular nausea and vomiting induced by highly emetogenic chemotherapy, and to the treatment of such nausea and vomiting over multiple consecutive days. The

FIELD OF THE INVENTION The present invention relates to the use of centrally acting NK.sub.1 antagonists to treat nausea and vomiting, particular nausea and vomiting induced by highly emetogenic chemotherapy, and to the treatment of such nausea and vomiting over multiple consecutive days. The

FIELD OF THE INVENTION The present invention relates to the use of centrally acting NK.sub.1 antagonists to treat nausea and vomiting, particular nausea and vomiting induced by highly emetogenic chemotherapy, and to the treatment of such nausea and vomiting over multiple consecutive days. The

FIELD OF THE INVENTION The present invention relates to the use of centrally acting NI.sub.1 antagonists to treat nausea and vomiting, particular nausea and vomiting induced by highly emetogenic chemotherapy, and to the treatment of such nausea and vomiting over multiple consecutive days. The

FIELD OF THE INVENTION The present invention relates to the use of centrally acting NK.sub.1 antagonists to treat nausea and vomiting, particular nausea and vomiting induced by highly emetogenic chemotherapy, and to the treatment of such nausea and vomiting over multiple consecutive days. The

FIELD OF THE INVENTION The present invention relates to the use of S-alkylisothiouronium derivatives, including, but not limited to, S-ethylisothiouronium diethylphosphate, for the prevention or treatment of headache, including but not limited to migraine, and for the prevention or treatment of

FIELD OF THE INVENTION The present invention relates to the use of S-alkylisothiouronium derivatives, including, but not limited to, S-ethylisothiouronium diethylphosphate, for the prevention or treatment of headache, including but not limited to migraine, and for the prevention or treatment of

RELATED APPLICATIONS This application is a U.S. National Phase application, filed under 35 U.S.C. .sctn. 371(c), of International Application No. PCT/GB2016/050998, filed on Apr. 11, 2016, which claims the benefit of and priority to United Kingdom Patent Application No. 1506116.1, filed on Apr. 10,

BACKGROUND OF THE INVENTION This invention relates to novel compositions of matter containing optically pure R(+) ondansetron. These novel compositions have potent antiemetic activity and are useful in ameliorating the nausea and vomiting otherwise induced by cancer chemotherapeutic agents and

FIELD OF THE INVENTION The present invention relates in general to methods for delivering therapeutic compounds across the blood-brain barrier of patients, and more particularly to the use of cannabinoids coupled to a chemotherapy agent for transport across the blood-brain barrier. BACKGROUND OF THE

BACKGROUND OF THE INVENTION The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, methods of using the propofol